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Abstract: The human ether-à-go-go channel (hEag1 or KV10.1) is a cancer-relevant voltage-gated
potassium channel that is overexpressed in a majority of human tumors. Peptides that are able
to selectively inhibit this channel can be lead compounds in the search for new anticancer drugs.
Here, we report the activity-guided purification and electrophysiological characterization of a novel
KV10.1 inhibitor from the sea anemone Anthopleura elegantissima. Purified sea anemone fractions
were screened for inhibitory activity on KV10.1 by measuring whole-cell currents as expressed
in Xenopus laevis oocytes using the two-microelectrode voltage clamp technique. Fractions that
showed activity on Kv10.1 were further purified by RP-HPLC. The amino acid sequence of the
peptide was determined by a combination of MALDI- LIFT-TOF/TOF MS/MS and CID-ESI-FT-ICR
MS/MS and showed a high similarity with APETx1 and APETx3 and was therefore named APETx4.
Subsequently, the peptide was electrophysiologically characterized on KV10.1. The selectivity of
the toxin was investigated on an array of voltage-gated ion channels, including the cardiac human
ether-à-go-go-related gene potassium channel (hERG or Kv11.1). The toxin inhibits KV10.1 with an
IC50 value of 1.1 µM. In the presence of a similar toxin concentration, a shift of the activation curve
towards more positive potentials was observed. Similar to the effect of the gating modifier toxin
APETx1 on hERG, the inhibition of Kv10.1 by the isolated toxin is reduced at more positive voltages
and the peptide seems to keep the channel in a closed state. Although the peptide also induces
inhibitory effects on other KV and NaV channels, it exhibits no significant effect on hERG. Moreover,
APETx4 induces a concentration-dependent cytotoxic and proapoptotic effect in various cancerous
and noncancerous cell lines. This newly identified KV10.1 inhibitor can be used as a tool to further
characterize the oncogenic channel KV10.1 or as a scaffold for the design and synthesis of more potent
and safer anticancer drugs.
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1. Introduction
Cancer is still one of the leading causes of death worldwide. In 2012 about 14.1 million new cancer
cases and 8.2 million cancer deaths were reported [1]. The WHO reports that in 2015, the number of
cancer deaths has risen to 8.8 million. This corresponds to nearly 1 in 6 deaths [2]. Since the population
continues to grow and age, these numbers are expected to increase. It is predicted that there will be
21.7 million new cancer diagnoses and 13 million cancer deaths in 2030. These numbers are probably
even an underestimation since the increased cancer risk in developing countries due to poor diet,
smoking etc. was not taken into account [1,3]. It is clear that the burden of cancer should be reduced.
Therefore, there is an urgent need for more effective and safer anticancer drugs.
The voltage-gated potassium channel human ether-à-go-go 1 (hEag1, KV10.1) represents an
interesting cancer target because it is overexpressed in a wide range of human tumor cells and
tissues [4–10] but is virtually undetectable in healthy tissue outside the central nervous system
(CNS) [6,11–13]. Overexpression of rat Eag1 in NIH-3T3 cells induced features that are characteristic for
malignant cell transformation [14]. Since then, several approaches inhibiting either channel expression
or activity by siRNA [15], small molecules [16–18] and monoclonal antibodies [19,20] has led to
inhibition of proliferation of tumor cells both in vitro and in vivo. Unfortunately, in vivo efficacy and
selectivity remains a major issue for most of these compounds. Many small compounds, such as
astemizole and imipramine, also block the cardiac human Eag-related gene (hERG, KV11.1) and can
therefore be arrhythmogenic [21,22].
Although several venom peptides are known to exhibit therapeutic effects by interacting with
ion channels [23], only one venom peptide, κ-hefutoxin 1, has been described in literature to show an
inhibitory effect on the KV10.1 channel [24]. This peptide was originally isolated from the venom of
the Asian forest black scorpion Heterometrus fulvipes by Srinivasan and colleagues [25].
In order to identify novel KV10.1 inhibitors, we electrophysiologically screened fractions
of the sea anemone Anthopleura elegantissima. The marine environment is considered to be an
underexploited but very interesting source of novel anticancer drugs [26–31]. Moreover, compounds
extracted from venomous marine invertebrates, such as sea anemones, contain a wide array of
bioactive compounds [32,33]. An interesting example is the ShK peptide from the sea anemone
Stichodactyla helianthus, which is able to block both KV1.1 and KV1.3 in the low picomolar range.
An analogue of this peptide, named Dalazatide (Shk-186)) with improved selectivity for KV1.3 was
developed [34] and has currently completed Phase I clinical trials for the treatment of autoimmune
diseases [35,36].
In this work, we present the identification of a novel sea anemone peptide APETx4.
The effect of this peptide on KV10.1 and other ion channels was electrophysiologically investigated.
The antiproliferative, cytotoxic and pro-apoptotic activity of APETx1 was evaluated on various
cancerous and non-cancerous cell lines.
2. Results
2.1. Activity-Guided Purification and Identification of A Novel KV10.1 Inhibitor
To identify novel inhibitors of the potassium channel KV10.1, previously purified fractions from
the sea anemone A. elegantissima [37] were screened for inhibitory activity on KV10.1. The fraction
showing inhibitory effect was further purified by RP-HPLC. The monoisotopic molecular mass of the
purified peptide was determined by MALDI-TOF MS (4651.02 Da) and ESI-FT-ICR MS (4650.9974 Da)
(Figure S1).
Reduction of the peptide by TCEP yielded a monoisotopic molecular mass of 4657.0334 Da
using ESI-FT-ICR MS. This data indicates that 3 disulfide bonds are present in the purified, oxidized
peptide (Figure S2). This molecular mass does not correspond to any known compounds derived from
A. elegantissima. The sequence of this novel peptide was determined by a combination of Post-Source
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Decay analysis (MALDI-LIFT-TOF/TOF MS/MS) and Collision-Induced Dissociation (CID-ESI-FT-ICR
MS/MS). The determined amino acid sequence and MS/MS spectra are shown in Figure 1.Mar. Drugs 2017, 15, 287    3 of 17 
 
 
Figure  1. MS/MS  spectra  characterizing  the APETx4  sequence.  (A) MALDI‐PSD‐TOF/TOF  of  the 
[M+H]+ species @m/z 4651.02 and (B) ESI‐FT‐ICR MS/MS (CID) of the [M+4H]4+ species @m/z 1163.76. 









Figure 1. MS/MS spectra characterizing the PETx4 sequence. (A) MALDI-PSD-TOF/TOF of the
[M+H]+ species @m/z 4651.02 and (B) ESI-FT-ICR S/ S (CID) of the [M+4H]4+ species @m/z 1163.76.
The combination of the two spectra led to the characterization of the whole sequence (34 peptide bonds
broken over 38). The isobaric amino acids L and I have been attributed by sequence homology with
APETx1 and APETx3.
A standard protein Basic Local Alignment Search (BLAST, NCBI) using the blastp algorithm
was performed and 26 Blast hits ere identified. Only 11 of these hits were found in the UniprotKB
Protein knowledgebase to exist with experim n l evidence at the protein lev l. All of them originate
from the Actiniidae family, which is the largest and most diverse family of the Actiniaria order
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(sea anemones) [38]. A multiple sequence alignment of the purified peptide with these 11 homologues
sea anemone peptides is shown in Figure 2.Mar. Drugs 2017, 15, 287    4 of 17 
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Figure 2. In the upper panel, a multiple sequence alignment of APETx4 and its homologous sea
anemone peptides is shown. Peptide na es reco ended by UniProt and alternative names are
given. A Clustal Omega sequence alignment was performed using CLC Main Workbench. Amino acid
residues are color d according to the RasMol amino col r scheme. Percentages of identity (% ID) were
obtain d usi g standard protein BLAST. In the low r panel, the amino acid sequence of APETx4 was
modeled on an averaged structu ed obtained from the solution NMR structure of APETx1 (P ID:
1WQK) using Modeller and Chimera. The amino acid res u are colored according to the RasMol
amino color scheme. The 5 amino acid residues that differ between APETx1 and APETx4 are displayed
as sticks. The C- and N-terminal residues and the cysteine residues (4, 6, 20, 30, 37 and 38) are indicated.
The novel peptide shows an 88% and an 86% identity to respectively APETx1 and APETx3 and
was therefore named APETx4 (Figure 2). If the nomenclature suggested by King and colleagues [39,40]
is followed, the peptide can be named κ-actitoxin-Ael2e or in short κ-AITX-Ael2e. The amino acid
sequence of APETx4 was deposited in the UniProt Knowledgebase ( niProtKB) under accession
number C0HL40.
Due to he high sequence similarity bet x4 and APETx1, the solution NMR str cture
of APETx1 (PDB ID: 1WQK) was used as a te ology modeling of APETx4. First, an
average structure of the 25 final solution st t f PETx1 was generated in Chimera. Secondly,
a homology model of the target sequence of x4 fro the template APETx1 was made using
Modeller and Chimera (Figure 2 and Figure S3).
2.2. APETx4 Is A Gating Modifier of KV10.1
Once the active peptide was purified and identified, the effect of APETx4 on KV10.1 was further
electrophysiologically characterized. After addition of 1.6 µM APETx4, a 76 ± 2% inhibition of the
outward current was observed. To investigate the effect of APETx4 on the rate of activation, the evoked
KV10.1 currents were fitted with the exponential equation y = y0 + ymax (1 – e−t/τ), where y0 is the
evoked current at t = 0 s, ymax is the maximum current, and τ is the time constant. APETx4 appears
to reduce the rate of KV10.1 activation. In control conditions, the time constant τ was 376 ± 60 ms.
After toxin addition (1.6 µM), τ increased to 1209 ± 229 ms (n = 3, p < 0.05) (Figure 3A). The rise time tr
(ms) was also calculated from the raw data and refers to the time the current rises from 10% to 90% of
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its final value. APETx4 increased the rise time from 653 ± 42 ms in control conditions to 1246 ± 96 ms
(n = 3, p < 0.05).Mar. Drugs 2017, 15, 287    5 of 17 
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Figure 3. t tion- and state-d pendent effect of APETx4 on evoked KV10.1 currents.
(A) Repr sen ative KV10.1 current evoked by a 2 s pulse t 0 mV from the hold g potential in
control and toxin condition are shown in light gray. An exponential one phase association equation was
used o fit the evoked currents (black lines); (B) Concentration-de endency plot fitted with a logistic
equation s ows the current i hibition (%) in function of APETx4 concentration; (C) Th normalized
current (I/Imax) was plotted versus the APETx4 incubation time. The time points were fitted with a
one-phase decay exponential equation; (D) The state-dependency plot shows the normalized current
in control conditions and in toxin condition. During the APETx4 addition the cell membrane potential
was clamped at −90 mV for 10 min. All measurements were performed in external ND96 solution.
A concentration-response curve was generated by measuring the current inhibition (%) as a
function of increasing concentrations. The data points were fitted with a logistic sig oid function, the
calculated IC50-value was 1.01 ± 0.01 µM, the Hill coefficient was 3.8 ± 0.3 and the maximal current
inhibition was 88.3 ± 0.9% (F gure 3B). Figure 3C shows th observed normalized current (I/Imax)
versus th incubation time with APETx4. The time poi t w re fitted with the exponential one phase
decay equation y = y∞ + (y0 − ∞) e−t/τ, where y∞ represents the normalized current that s reached at
infinite times (plat au) and y0 is the normaliz d current before toxin addition. After addition of 1.6 µM
APETx4, the observed normalized current gradually decreased with a time constant of τ = 97 ± 7 s.
The state-dependency of the inhibition was studied by holding the cell potential at −90 mV for
10 min during the addition of 1.6 µM APETx4 to the oocyte. After keeping the channels in a closed
state at the holding potential, the normal pulse protocol to 0 mV was resumed. The current upon
the first stimulation was reduced by 85.2 ± 1.9% in comparison with the control current measured
before toxin addition. This seems to indicate that the toxin is able to bind the channel in its closed state
(Figure 3D).
APETx4 modifies the voltage dependence of KV10.1. In the presence of 1.6 µM APETx4, a
17.7 ± 1.1 mV shift of the activation curve towards more positive potentials was observed (n = 3;
p < 0.05). The half-maximal voltage (V1/2) shifted from 26.4 ± 0.9 mV in control condition to
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44.1 ± 0.7 mV after addition of 1.6 µM APETx4. The slope factor k shifted from 20.7 ± 0.6 mV






























Figure 4. Voltage-dependent effect of APETx4 on evoked KV10.1 currents. (A) Normalized currents
elicited in ND96 solution (2 K ) ere plotted versus the applied pulse potentials (mV) in control
( ) and toxin condition (#). e ata oints were fitted with the Boltzmann equation; (B) Normalized
currents elicited in l i (96 mM Ko) w re plotted versus the applied puls potentials (mV)
in control ( ) and toxin condition (#). The data points were fit ed wi h the Boltzma n equation;
(C) The inhibited current (%) observed after 1.6 µM APETx4 addition in ND96 (#) and HK ( ) solution
was plotted versus the applied pulse potentials; (D) Effect of APETx4 on the inactivati n properties
of V10.1. The non-inactivating cha nel fraction (I2/I2,max) was plotted against the correspo ding
prepulse potential (mV) in control ( ) and toxin condition (#).
In a high potassium solution (HK solution, 96 mM Ko), V1/2 shifted from 41.3 ± 1.4 mV in control
condition to 50.9 ± 0.8 mV after addition of 1.6 µM APETx4, a shift of 9.6 ± 1.7 mV (n = 3; p < 0.05).
The slope factor shifted from 15.3 ± 1.4 in control condition to 13.9 ± 0.8 in toxin condition (n = 3, NS).
After toxin addition, no inward current was observed at negative pulse potentials (Figure 4B).
To investigate whether the percentage of current inhibition is also voltage-dependent, the
non-normalized i hibited current (1-It/Ic) was plott against th applied ac ivating potentials.
The current inhibition f KV10.1 by 1.6 µM APETx4 was reduced at more positive potentials. When a
depolarizing pulse from −90 mV to 0 mV was applied, an inhibition of 79 ± 4% could be observed.
When a more depolarizing pulse was applied, for example to 65 mV from the holding potential, the
KV10.1 current was only reduced by 29 ± 6%. In a high potassium solution, a similar effect was
observed (Figure 4C).
In order to investigate the effect of APETx4 on the inactivation properties of KV10.1, a two-pulse
protocol was used as described in [17]. This protocol consists of a variable 1.5 s prepulse step, ranging
from −140 mV to 30 mV in 10 mV steps, followed by a 0.5 s test pulse to 30 mV. Figure 4D shows the
non-inactivating channel fraction (I2/I2,max) plotted against the corresponding prepulse potential. I2 is
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the peak current measured during the 30 mV test pulse, I2,max is the maximal peak current elicited by
the test pulse. No apparent inactivation was observed in control or toxin condition.
2.3. Effect of APETx4 on Different Voltage-Gated Ion Channels
APETx-like toxins are known to be promiscuous [41], therefore APETx4 was screened against a
panel of NaV and KV channels. At a concentration of 1.6 µM, APETx4 exhibited the highest activity on
KV10.1 (n = 3). No significant inhibition was observed for KV1.1 (n = 11) and KV11.1 (n = 3). Inhibitions
of 50% or less were observed for NaV1.4 (n = 5), NaV1.5 (n = 5), NaV1.6 (n = 3), KV1.3 (n = 6), KV1.5
(n = 3) and KV2.1 (n = 4). A higher percentage of inhibition was observed for KV1.4 (n = 3) (Figure 5).
Figure S4 shows representative traces in control conditions and after addition of 1.6 µM APETx4 of all
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Figure 5. Selectivity screening on a panel of NaV V cha nels. The curre t inhibition (%) observed
after ddition of 1.6 µM APETx4 to various cha is displayed in a ba graph. Values are shown as
average ± SEM of at least 3 independent e ri ents.
Since most inhibitors of KV10.1 also inhibit the cardiac hERG channel, the effect of APETx4 on
hERG was further investigated.
After additio of 1.6 µM or even 10 µM (10 × IC50) APETx4, no significant inhibition of the
hERGtail curr nt was obs rved. Since the inhibition of KV10.1 by APETx4 and of hERG by APETx1 is
voltage-dependent, the voltage-dependent effect of 10 µM APETx4 on hERG was also investigated.
Normalized current-voltage relationship of the inward tail currents were fitted with the Boltzmann
equation. A 7.7 ± 0.4 mV (n = 3, p < 0.05) shift of the activation curve towards more positive potentials
was observed after the addition of 10 µM APETx4 (Figure 6A). The highest inhibition of the tail current
(21 ± 5%) was obtained after an activating step to −20 mV. The tail current increased during activation
steps to positive potentials (≥0 mV) after APETx4 addition (Figure 6B).
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Figure 6. Voltage-dependent effect of APETx4 on hERG inward tail currents. (A) Normalized inward
tail currents were plotted versus the applied pulse potentials (mV) in control ( ) and toxin condition
(#). The data points were fitted with the Boltzmann equation. (B) The inhibited current (%) observed
after 10 µM APETx4 addition was plotted versus the applied pulse potentials.
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2.4. Effect of APETx4 on Cancerous and Non-Cancerous Cell Lines
To investigate whether the observed electrophysiological effects on KV10.1-expressing oocytes can
be translated into anticarcinogenic in vitro effects, several high-throughput live-cell imaging assays
were performed. Proliferation, cytotoxicity and apoptosis assays were performed on 5 different cell
lines using the IncuCyte ZOOM system. Table 1 gives an overview of the used cell lines and their
presumed KV10.1 expression level.
Table 1. Cell lines used for proliferation, cytotoxicity and apoptosis assays.
Cell Line Description KV10.1 Expression Level Ref.
SH-SY5Y Human neuroblastoma cell line High [20]
LNCaP Human prostate cancer cell line Undetectable [20]
NIH-3T3 Mouse embryonic fibroblast cell line Undetectable [14]
MDA-MB-435S Human melanoma cell line Moderate [20]
hTERT RPE-1 Human epithelial cell line Moderate [20]
The cell proliferation was quantified in terms of cell confluency (%) over time; data points were
collected every hour. APETx4 induced a concentration-dependent antiproliferative effect in all the
cell lines except in the healthy fibroblast cell line NIH-3T3. Since some of the affected cell lines do not
express KV10.1, f.e. LNCaP, it is presumed that the observed effect cannot only be attributed to KV10.1
inhibition (Figure S5).
Cytotoxicity was visualized and quantified by addition of the CellTox Green Dye over time.
This asymmetric cyanine dye can enter the nonviable cell once the membrane integrity is compromised.
This dye is unable to enter viable cells but binds DNA in (or released from) dead cells, thereby
enhancing its green fluorescence. All cell lines, except NIH-3T3 became nonviable after addition of
APETx4. Interesting to note is that the cytotoxic effect of high APETx4 concentrations on LNCaP and
hTERT RPE-1 appeared very rapidly (Figure S5).
The proapoptotic activity of APETx4 was visualized and quantified by the addition of the IncuCyte
Caspase-3/7 Reagent. This reagent is an inert and non-fluorescent substrate, which is cleaved by
activated caspase-3/7 during early apoptosis. The cleavage of the reagent releases a DNA-binding
green fluorescent dye. Similar to the effects observed during the antiproliferative and cytotoxic
assays, proapoptotic effects were observed for all the cell lines except for NIH-3T3. In Figure 7 an
overview is given for the caspase assays of all the tested cell lines. The green object count (1/mm2) is
plotted against the incubation time: A gradual increase in green fluorescent cells was observed for the
KV10.1-expressing cancerous cell lines SH-SY5Y and MDA-MB-435S. A very rapid response (<60 min)
was observed for the cancerous cell line (no KV10.1 expression) LNCaP and the KV10.1-expressing
noncancerous cell line hTERT RPE-1.
Figure S6 provides images taken by the IncuCyte Zoom System for each cell line at 0 h, 24 h and
48 h after changing the growth medium by medium containing 0 µM or 50 µM APETx4. These images
show that immediately after toxin addition, the LNCAP and hTERT RPE-1 cells became less viable.
For SH-SY5Y and MDA-MB-435S these immediate effects were not clearly observed. Similar images
were obtained for the fibroblast cell line NIH-3T3 in control and toxin (50 µM APETx4) condition.










Figure 7. Investigation of the proapoptotic effect of arious cell lines using a Caspase-3/7
Reagent. The amount of cells in early apoptosis was l bject Count (1/ m2) versus
time (hours). The dat points represented as r l s ere obtained from apoptosis experiments
with cells incubated without APETx4, the gre resent experiments with 20 µM APETx4
and the blue cir les wer obtained from experi ents it µ PETx4.
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3. Discussion
3.1. APETx4 Is a Gating Modifier that Presumably Binds to the Voltage Sensor Paddle of KV10.1
Here, we identified a novel sea anemone toxin (APETx4) that inhibits the KV10.1 currents in a
concentration- and voltage-dependent manner by binding to the channel in its closed state. We propose
that the mode of action of APETx4 on KV10.1 is similar to that of APETx1 on hERG [42]. Both toxins
shift the activation curve towards more positive potentials. This results in a lower current inhibition
(%) at more depolarized potentials, when more channels are open. Our data indeed suggest that
APETx4 binds to closed KV10.1 channels and reduces the activation rate. More depolarized pulse
potentials are necessary to evoke KV10.1 currents in the presence of APETx4. A high external potassium
concentration (HK) results in small inward currents at a membrane potential around−20 mV in control
condition. However, in the presence of APETx4, no inward currents were observed. This suggests that
at these negative potentials, the channel is kept in a closed conformation by APETx4. We hypothesize
that like APETx1, APETx4 is a gating modifier that presumably binds to the S3b-E2-S4 region (voltage
sensor paddle) of KV10.1. The high Hill coefficient (~4) suggests possible co-operativity. Co-operativity
was also suggested for the interaction between the gating modifier saxitoxin (STX) and hERG [43].
STX also slows down the channel opening and stabilizes the closed state of hERG channels. However,
more in depth whole-cell patch clamp experiments as described in [43] are necessary to confirm our
hypothesis of cooperative binding.
APETx1 is proposed to bind to the voltage sensor paddle of hERG. In particular, the negative
charge of E518 is expected to form an electrostatic interaction with the toxin [44]. Several other kinds of
gating modifier toxins also bind to the extracellular exposed part of the S3–S4 domain. More precisely
by binding to a glutamic acid residue and several hydrophobic amino acid residues [45]. An example
of these toxins is Hanatoxin (HaTx1) from the tarantula Grammostola spatulata. This toxin modifies the
channel gating of KV2.1 by binding to two hydrophobic (I273 and F274) residues and to a glutamic acid
residue (E277) [46]. Takahashi et al., suggest that the combination of a hydrophobic patch and charged
amino acid residues on the toxin surface is responsible for the binding of gating modifiers to ion
channels [47]. Figure S3 shows that APETx4 contains such a hydrophobic patch and charged residues
on one side of the toxin. A sequence alignment of several known gating modifiers (Figure 8), shows
that many of them, including APETx4 consist of a hydrophobic triad. Wang and colleagues showed
that the active surface of the gating modifier SGTx is composed of a patch of important hydrophobic
residues; Y4, L5, F6 and W30 [48]. The hydrophobic residues Y32, F33 and L34 of APETx4 correspond
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Figure 8. A multiple sequence alignment of various gati ifier toxins was performed using
Clustal Omega (EMBL-EBI). Cysteine residues are highlig te i grey and the hydrophobic residues;
Y4, L5, F6 that are functionally important for the activity of S Tx on the KV2.1 channel.
3.2. APETx4 Is Able to Distinguish the Oncogenic KV10.1 Channel from the Cardiac hERG Channel
The drawback of many KV10.1 inhibitors is that they inhibit hERG with a similar or higher affinity.
Inhibition of this cardiac channel can cause long QT syndrome, which can lead to arrhythmia and
sudden death [49]. However, hERG is also overexpressed in several cancer cells and human tumors
Mar. Drugs 2017, 15, 287 11 of 17
and is therefore also an anticancer target [50–52]. Since hERG liability is a very important factor in early
drug discovery, we investigated the effect of APETx4 on hERG currents. APETx4 exerts no inhibitory
effect on hERG at a concentration of 1.6 µM. Even at a concentration that is 10 times higher than the
IC50 for KV10.1 (10 µM), the tail current is not significantly inhibited when a prepulse of 40 mV is
followed by a pulse to−120 mV. However, since APETx1 displays a voltage-dependent effect on hERG,
we investigated the current-voltage relationship of the action of APETx4 on hERG. After addition of
10 µM APETx4, a shift towards more positive potentials was observed. When the non-normalized
inhibited current was plotted against the activating prepulse potentials, a maximum inhibition of the
inward tail current by 21 ± 5% was observed after a prepulse of −20 mV. At concentrations in the low
micromolar range, APETx4 discriminates between KV10.1 and hERG.
APETx1, which is highly similar to APETx4 (88% identity), inhibits hERG currents with an IC50
value of 34 nM [42]. A 300-fold concentration of APETx4 is not able to inhibit the inward hERG
current. APETx1 is also not able to significantly inhibit KV10.1, at least not at a concentration of
100 nM [44]. Higher concentration of this toxin might be able to inhibit the KV10.1 currents. This would
be interesting to explore further in order to fully understand the selectivity of APETx1 for hERG over
KV10.1 and of APETx4 for KV10.1 over hERG. The related toxin APETx3, which only differs from
APETx1 by one amino acid and shows an 86% amino acid identity to APETx4, is also not able to inhibit
the hERG current at concentrations up to 50 µM [41]. However, this naturally occurring mutant of
APETx1 is able to inhibit KV10.1 currents by 80% at a concentration of 2 µM (n = 2, unpublished data).
The only difference between APETx1 and APETx3 is one amino acid substitution from a threonine
residue to a proline residue. This single mutation completely changes the selectivity profile of the
toxin from a potent hERG inhibitor to a NaV channel modulator. This functional difference can result
from the introduction of a structural kink in the peptide by the proline residue [41]. APETx4 contains
a threonine residue on the third position, similarly to APETx1. APETx2, a potent ASIC3 inhibitor
(IC50 ∼ 63 nM) [53] and a weaker hERG inhibitor (IC50 ∼ 1.2 µM) [54], shows no effect on KV10.1 at
2 µM (n = 3, unpublished data).
3.3. The In Vitro Cytotoxic Effect of APETx4 Does not Only Result from Its Effect on KV10.1
Similarly to other APETx-like peptides [41,54], APETx4 is not a selective inhibitor. Besides
KV10.1, APETx4 is also able to inhibit several other KV and NaV channels. However, since natural
point mutations in APETx-like peptides can lead to crucial changes in the pharmacological profile of
the peptides [41], synthetically produced analogues of APETx4 can result in more potent and more
selective KV10.1 inhibitors.
The antiproliferative, cytotoxic and proapoptotic effects of APETx4 were evaluated on several
cancerous and non-cancerous cell lines. APETx4 was able to induce a dose-dependent effect on all
cell lines except on the murine fibroblast cell line NIH-3T3. Even cell lines that presumably do not
express KV10.1 on its surface were affected. Although the expression levels of KV10.1 are not constant
during the cell cycle and this makes the interpretation of proliferation and cell viability data more
complex [55] we presume that the effect of APETx4 does not only result from its inhibitory activity
on KV10.1. Interesting to note is that the cytotoxic effects on LNCaP and hTERT RPE-1 cell lines
appear very rapidly. The mode of action of cytotoxic peptides can be explained by two nonexclusive
mechanisms. The peptides can form new ion channels in the cell membrane and/or they bind to
existing ion channels/membrane receptors to modify their activity [56]. Since the cytotoxic effect
is not observed in the NIH-3T3 cells or Xenopus oocytes, it is unlikely that APETx4 is a cytotoxic
channel-forming peptide. We therefore suggest that APETx4 exerts its effect through the binding to
unknown membrane proteins. More research is necessary to identify the main targets of APETx4 and
to unravel its mode of action.
In conclusion, a novel peptide from the sea anemone Anthopleura elegantissima was purified
and identified as an APETx peptide. This peptide, named APETx4, is able to inhibit the oncogenic
potassium channel KV10.1 in a concentration-, voltage- and state-dependent manner. The modulation
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of KV10.1 by APETx4 is reminiscent of the modulation of KV11.1 (hERG) by APETx1. However, APETx4
makes a clear distinction between KV10.1 and hERG at low micromolar concentrations. APETx4 is not a
highly selective KV10.1 inhibitor since it is also able to block several KV and NaV channels. Since natural
mutants of APETx4 show very different selectivity profiles it could be possible that synthetic analogues
show more selectivity for KV10.1. Moreover, APETx4 induces a concentration-dependent cytotoxic
and proapoptotic effect in various cancerous and in KV10.1-expressing cell lines without affecting the
proliferation of healthy fibroblast cells. More research is necessary to unravel the mechanism of action
of this peptide and to pinpoint its exact binding sites on KV10.1 and its other targets. The identification
of this novel KV10.1 inhibitor can be the first step in the design and synthesis of more potent and
selective anticancer compounds.
4. Materials and Methods
4.1. Purification of APETx4
A crude water-methanol extract of the sea anemone Anthopleura elegantissima was fractionated as
described previously [37]. These fractions were electrophysiologically screened for activity on KV10.1.
Active fractions were further purified by reverse-phase high-performance liquid chromatography
(RP-HPLC) as described for the purification of APETx3 by Peigneur and colleagues [41].
4.2. Biochemical Characterization and Sequence Analysis
The molecular mass of the purified peptide was measured by MALDI-TOF MS (4800 Analyzer,
Applied Biosystems) in positive ion reflectron mode and by ESI-FT-ICR MS (SolariX 9.4T, Bruker,
Fällanden, Switzerland) analysis in positive ion mode. The peptide sequence was determined by a
combination of MALDI- LIFT-TOF/TOF MS/MS (UltrafleXtreme, Bruker) and ESI-FT-ICR MS/MS
(CID, SolariX 9.4T, Bruker). For MALDI-LIFT-TOF/TOF experiments, the dried-droplet method
was used to deposit the peptide. Less than 1 mg of the peptide has been dissolved into 200 µL of
H2O/Formic Acid (0.1%), leading to a primary solution (PS) at a concentration below 1 mM. 1 µL of
this PS has been deposited together with 1 µL of 2,5-dihydroxibenzoic acid as a matrix (20 mg/mL
in 50-50 H2O/FA 0.1%-ACN (v/v) onto a MALDI plate (384 positions, Bruker Daltonics, Bremen,
Germany). MS spectra were acquired in reflector mode in the mass range m/z 700–5000 and analyzed
by FlexAnalysis 3.4 (Bruker Daltonics software). MS/MS experiments were performed using the
LIFT cell for post-acceleration of the metastable fragments. Before MS/MS analysis, the peptide
was reduced to remove the disulfide bridges. The reduction was achieved by incubating APETx4
with Tris-(carboxyethyl)phosphine at 200 mM (final concentration) for 50 min at 56 ◦C. The reduced
sample was then purified using a microcolumn ZipTip C18. Exact mass measurements and additional
MS/MS experiments have also been conducted using ESI-FT-ICR mass spectrometry. 1 µL of the PS
has been diluted with 99 µL of 50-50 H2O/FA 0.1%—ACN (v/v) to reach a concentration of ~10 µM.
The acquisition was performed from m/z 100 to 2000. CID experiments were conducted by isolating
the [M+4H]4+ species detected at m/z 1163.75663 and by fragmenting these ions in the collision cell
using a collision energy of 35 V. Fragment ions have finally been detected in the ICR cell.
4.3. Expression of Voltage-Gated Ion Channels in Xenopus Laevis Oocytes
For the expression of the ion channels (rNaV1.4, hNaV1.5, mNaV1.6, hKV1.1, rKV1.3, hKV1.4,
hKV1.5, hKV2.1, hKV10.1a and hKV11.1,) in Xenopus oocytes, the plasmids were linearized
and subsequently transcribed using the T7 or SP6 mMESSAGE-mMACHINE transcription kit
(Ambion®, Carlsbad, CA, USA).
Stage V-VI Xenopus laevis oocytes were isolated by partial ovariectomy. The animals were
anesthetized by a 15 min submersion in 0.1% tricaine methane sulfonate (pH 7.0). Isolated oocytes
were defolliculated with 2 mg/mL collagenase.
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Defolliculated oocytes were injected with 50 nL of cRNA at a concentration of 1 ng/nL using a
micro-injector (Drummond Scientific®, Broomall, PA, USA). The oocytes were incubated in a solution
containing (in mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.4), supplemented with
50 mg/L gentamycin sulfate.
4.4. Electrophysiological Recordings
Two-electrode voltage-clamp recordings were performed at room temperature (18–22 ◦C) using
an Geneclamp 500B Voltage and Patch Clamp Amplifier (Axon Instruments, Union City, CA, USA,
controlled by a Axon Digidata 1550 Low-Noise Data Acquisition System (Axon Instruments). Whole
cell currents from oocytes were recorded 1–4 days after injection. The normal bath solution (ND96)
composition was (in mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.4). The high
potassium solution (HK) composition was in mM): NaCl, 2; KCl, 96; CaCl2, 1.8; MgCl2, 2 and HEPES,
5 (pH 7.4). Voltage and current electrodes were filled with 3 M KCl. Resistances of both electrodes
were kept between 0.5 and 1.5 MΩ. The elicited KV1.x end KV2.1 currents were filtered at 500 Hz and
sampled at 2 kHz, KV10.1 currents were filtered at 1 kHz and sampled at 2 kHz, hERG currents were
filtered at 1 kHz and sampled at 10 kHz and the sodium currents were filtered at 2 kHz and sampled at
20 kHz using a four-pole low-pass Bessel filter. Leak subtraction was performed using a -P/4 protocol.
KV10.1 currents were evoked by 2 s depolarizing pulses to 0 mV from a holding potential of
−90 mV. KV11.1 (hERG) peak and tail currents were generated by a 2.5 s prepulse from −90 mV
to 40 mV followed by a 2.5 s pulse to −120 mV. KV1.x channel currents were evoked by 500 ms
depolarizations to 0 mV from a holding potential of −90 mV followed by a 500 ms pulse to −50 mV.
KV2.1 currents were elicited by 500 ms pulses to +20 mV from a holding potential of −90 mV. NaV
currents were evoked by a 100 ms depolarizations to 0 mV from the holding potential.
To investigate the concentration-dependency, the KV10.1 current inhibition (%) was measured
after addition of 7 varying APETx4 concentrations. The curve was fitted with the logistic dose-response
equation, y = A1−A21+ (IC50/[toxin])nH + A2 where y represents the percentage of current inhibition, A1 the
initial inhibition at the lowest toxin concentration (0%), A2 the final inhibition at the highest toxin
concentration, IC50 the half maximal inhibitory toxin concentration and nH the Hill coefficient.
The voltage-dependent activation of the KV10.1 channels was investigated by 1000 ms activating
steps from the holding potential −90 mV to 65 mV with 5 mV increments. The normalized current
amplitudes were plotted against the corresponding pulse potentials and fitted with the Boltzmann
equation, y = A1−A2
1+ e(V−V1/2)/k
+ A2, where y represents the normalized current (I/Imax), A1 is the initial
y-value(-∞) and A2 is the final y-value, Imax is the maximal current, V is the test voltage, V1/2 is the
half-maximal voltage and k is the slope factor.
The voltage-dependent inactivation of KV10.1 channels was studied by 1.5 s prepulses from the
holding potential ranging from −140 mV to 30 mV with 10 mV steps. These pulses were followed by a
0.5 s test pulse to 30 mV [17]. The normalized peak current amplitudes (I2/I2,max) measured during
the test pulse and were plotted against the prepulses and fitted with the Boltzmann equation.
The peak and tail current of hERG were measured at different voltages by 1500 ms activating
pulses from −60 mV to 55 mV in 5 mV steps from the holding potential of −90 mV, followed by a
750 ms step to −120 mV.
4.5. Live Cell Imaging
4.5.1. Cell Cultures
Cell lines SH-SY5Y (ACC 209), LNCaP (ACC 256) and NIH-3T3 (ACC 59) were purchased from
DSMZ (Germany). MDA-MB-435S (HTB 129) and hTERT RPE-1 (CRL 4000) were obtained from ATCC
(USA). Cell lines were cultured in their recommended media supplemented with 10% or 15% FCS
(PAA laboratories, Cölbe, Germany) at 37 ◦C in humidified 5% CO2 atmosphere. An overview of the
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used cell lines is given in Table 2. All media were purchased from ThermoFisher Scientific (Waltham,
MA, USA).
Table 2. Cell lines used for proliferation, cytotoxicity and apoptosis assays.
Cell Line Description Medium
SH-SY5Y Human neuroblastoma cell line RPMI + 15% FCS
LNCAP Human prostate cancer cell line RPMI + 15% FCS
NIH-3T3 Mouse embryonic fibroblast cell line DMEM + 10% FCS
MDA-MB-435S Human melanoma cell line RPMI + 10% FCS
hTERT RPE-1 Human epithelial cell line
DMEM:F12 + 10% FCS
+ 10 µg/mL Hygromycin B
4.5.2. Proliferation, Cytotoxicity and Apoptosis Assays
Cell proliferation, cytotoxicity and apoptosis were assessed in a 96-well microtiter plate by
live-cell imaging using an IncuCyte Zoom System (Essen BioScience, Welwyn Garden City, UK).
Cell proliferation was monitored in terms of cell confluency (%). Cell cytotoxicity was assessed by the
CellTox Green Dye assay (Promega, Madison, WI, USA). The IncuCyte Caspase-3/7 apoptosis assay
(Essen BioScience, UK) was used to evaluate the effect of APETx4 on the apoptotic pathway.
4.6. Data Analysis and Molecular Modelling
All electrophysiological data are presented as means ± S.E.M of n ≥ 3 independent experiments
unless otherwise indicated. All data were acquired using pClamp Clampex 10.4 Molecular Devices,
Downingtown, PA, USA) and analyzed using pClamp Clampfit 10.4 (Molecular Devices) and OriginPro
8 (Originlab, Northampton, MA, USA) or GraphPad Prism 6 software (GraphPad Software, Inc.,
San Diego, CA, USA). Paired student’s t-tests were performed to compare 2 sample means (p < 0.05).
Live-cell imaging data were collected from the IncuCyte Zoom software and analyzed using
GraphPad Prism 6 software. Proliferation was measured as Phase Object Confluence (%), cytotoxicity
and apoptosis were measured as Green Object Count (1/mm2). Data points were collected every hour.
In order to improve the clarity of the graphs, only the data points for every 5 h are shown. All data are
represented as mean ± S.E.M of n = 4 different wells.
Homology modeling was performed using Chimera 1.10.1 [57] enhanced with the Modeller 9.14
software [58].
Clustal Omega multiple sequence alignments were performed using CLC Main Workbench
(QIAGEN, Aarhus, Denmark) or EMBL-EBI [59]. The following UNIPROT entry identifiers were used
for Figure 2; P61541, B3EWF9, P86461, P61542, G0W2H8, P86470, G0W2H8, P86464, P86462, P84919
and Figure 8; P61541, B3EWF9, P61542, P60590, P60980, P83480, P56854, P56852.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/9/287/s1,
Figure S1. Determination of the monoisotopic molecular mass of APETx4, Figure S2. ESI-FT-ICR spectra of
oxidized and reduced APETx4, Figure S3. Homology modeling of APETx4, Figure S4. Selectivity screening on a
panel of NaV and KV channels, Figure S5. Investigation of the antiproliferative and cytotoxic effects of APETx4 on
various cell lines. Figure S6. Cell images of various cell lines during apoptosis experiments.
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